



# Canadian MDx Firm Gets Investment from OGI

March 13, 2009

**Newsletter:** [GenomeWeb Daily News](#)

NEW YORK (GenomeWeb News) - The Ontario Genomics Institute today said that it has invested an undisclosed amount in Cytogenomix, a London, Ontario-based developer of cytogenetic DNA probes for potential use in diagnostics.

The firm is developing single cell DNA probes that are smaller and more densely distributed across chromosomes than probes that are currently commercially available, said OGI. These fluorescent probes can be designed to specifically target and detect chromosomal abnormalities, such as those underlying cancer.

"The investment from OGI will help us in the development of more probes for more genetic diseases, building on the existing 400 probes for around 100 diseases," said Peter Rogan, co-founder of Cytogenomix. "Our long-term goal is to manufacture probes that doctors could use to diagnose literally hundreds of disorders on the spot."

OGI's investment was made through its Pre-commercialization Business Development Fund program.

A promotional banner for Arrowhead Conferences. On the left, the logo "ARROWHEAD CONFERENCES" is displayed in white and blue on a green background, with the word "PRESENTS" below it. To the right, the text "The 2009 Personalized Medicine Conference" is written in large white letters, followed by "New Developments in Pharmacogenomics, Biomarkers and Molecular Diagnostics" in smaller white text. Below this, the dates "April 23rd - 24th, 2009" and location "Baltimore, MD, USA" are listed in white. The background of the banner is a dark blue gradient with a faint globe image.

